New from the ROBUUST group in Cancers MDPI Farshad Sheybaee Moghaddam Dr. Hooman Djaladat #UTUC #Immunotherapy 🔗Free link access: mdpi.com/2072-6694/17/1…

🚨A fantastic review for non-clear cell renal cell carcinoma! in Nature Reviews Urology 👉Time to tailor, not generalize: 🔬 Genotype-driven subtyping (e.g. MET, FH, TSC-mTOR, ALK, MITF, SMARCB1) enables precision therapy. 💊 Cabozantinib & savolitinib show promise in MET-driven tumors.

🚨 New in Nature Reviews Urology : Proud to co-first author a comprehensive review on the molecular & therapeutic landscape of non–clear cell renal carcinoma (nccRCC) — from MET-driven pRCC to SMARCB1-deficient RMC. 🔗 nature.com/articles/s4158… #KidneyCancer #UroOnc #RCC Reza Mehrazin, MD

I was lucky to attend the SP symposium and learn from SP experts. To stay ahead of the curve, it’s crucial to embrace innovation and leverage technology to maximize the benefits for our patients.

JUST IN: IMvigor011 in muscle-invasive bladder cancer (MIBC) hits both DFS & OS with PD-L1 inhibitor Atezolizumab in ctDNA+ population. Major news for Precision Oncology in adjuvant Solid Cancers! Natera Tom Powles Roche natera.com/company/news/i…